The LeMaitre Vascular Conundrum: A Cautionary Tale for Quality Focused Investors The recent market turmoil has left many investors scrambling to make sense of the volatility that has gripped the small cap space.
Riverwater Partners' latest investor letter highlights the struggles of medical device company LeMaitre Vascular, Inc. (NASDAQ:LMAT), which declined 12% in Q2 2026.
At first glance, this downturn may seem like a minor blip for quality focused investors who rely on LeMaitre Vascular's niche leadership and consistent execution.